NCT05238532View on ClinicalTrials.gov

Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of CT303 in Patients With ARDS

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 26, 2022

Primary Completion Date

February 22, 2023

Study Completion Date

February 22, 2023

Conditions
Acute Respiratory Distress Syndrome
Interventions
GENETIC

CT303

"Once a time, intravenous injection~* CT303 Starting Dose : 1.0\*10\^6 cells/kg~* CT303 Increasing Quantity Dose : 2.0\*10\^6 cells/kg"

Trial Locations (3)

13620

Seoul National University Bundang Hospital, Seoul

03080

Seoul national university hospital, Seoul

07061

Seoul national university boramae medical center, Seoul

Sponsors
All Listed Sponsors
lead

GC Cell Corporation

INDUSTRY